Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Mesothelioma × Bevacizumab × Clear all

Phase

Phase 2 3 Phase 1/2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Colorectal Neoplasms 12 Carcinoma, Hepatocellular 6 Colonic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Astrocytoma 2 Vipoma 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Recurrence 1 Progression Free Survival 1 Oropharyngeal Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Mesothelioma 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1 Laryngeal Neoplasms 1 Insulinoma 1 Inflammatory Breast Neoplasms 1 Hypopharyngeal Neoplasms 1

Interventions

Pemetrexed 4 Cisplatin 4 pembrolizumab 1 nintedanib 1 Carboplatin 1 Bevacizumab 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00651456 2023-03-13

MAPS

Intergroupe Francophone de Cancerologie Thoracique

Phase 2/3 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡